Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00559767 · ClinicalTrials.gov registry record
Mapping of End Stage Renal Disease Genetic Susceptibility in African Americans by Admixture Linkage Disequilibrium
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 2,860
- Enrollment target
NCT00559767: Completed study, sponsored by National Cancer Institute (NCI).
NCT00559767 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 2,860 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00559767 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 2,860 participants
- Enrollment target
Study Summary
This study will identify which regions on the genes, and genes themselves, may account for an increased risk of end stage renal disease (ESRD), that is, near-total loss of kidney function, for people of African American descent. Researchers will use a technique called admixture linkage disequilibrium (MALD) to study genomes, genetic material, in about 2,500 participants from two existing studies and participants who will serve as controls. ESRD disproportionately affects African Americans, who constitute 29% of all ESRD patients in the Medicare ESRD program. The disease can result from a variety of diseases, with diabetes as the leading underlying cause (44% of cases) and hypertension as the second leading cause (26%). The proportion of ESRD cases caused by diabetes has increased dramatically. Patients age 18 and older who are African American, who have ESRD, and who are participants of the FIND and CHOICE studies may be eligible for this study. FIND, or Family Investigation of Diabetes and Nephropathy, involves a multicenter study to identify susceptibility genes, that is, those with a risk, for diabetic and other forms of kidney disease. CHOICE, or Choices for Healthy Outcomes in Caring for ESRD patients is an ongoing study that identifies risk factors for cardiovascular outcomes in ESRD patients. The principle of mapping by MALD involves genetic variations that exist across populations. When mixing occurs between populations having different (heterogeneous) genes, the admixed offspring inherits chromosomes of distinct ancestry. However, over generations of mating, and recombination over several generations, originally large blocks of DNA from African ancestry have become part of smaller segments throughout the chromosome. The study will focus on risk alleles, that is, alternative forms of genes that carry a disease risk. Risk alleles are closely related to nearby ancestral gene markers found in a person. Patients will undergo a collection of blood and urine for
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,860 participants |
| Start Date | 2006-06-30 |
| Est. Completion | 2012-04-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00559767
The ClinicalTrials.gov registry entry for NCT00559767 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,860 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00559767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00559767 about?
NCT00559767 is a clinical study titled "Mapping of End Stage Renal Disease Genetic Susceptibility in African Americans by Admixture Linkage Disequilibrium". This study will identify which regions on the genes, and genes themselves, may account for an increased risk of end stage renal disease (ESRD), that is, near-total loss of kidney function, for people of African American descent. Researchers will use a technique called admixture linkage disequilibriu...
What is the current status of trial NCT00559767?
This trial is currently completed. The enrollment target is 2,860 participants. The study started on 2006-06-30. Estimated completion is 2012-04-10.
Who is sponsoring clinical trial NCT00559767?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.